Danielle E. Marcotulli, APN, John Theurer Cancer Center

Closing out their discussion on myelofibrosis management, experts from the John Theurer Cancer Center consider novel therapies under investigation and the future treatment paradigm.

Panelists consider the patient and disease factors that might indicate use of a specific JAK inhibitor when managing patients with myelofibrosis.

Broader perspectives on the optimal selection and sequencing of systemic therapy in patients diagnosed with myelofibrosis.

After reviewing the second patient scenario of myelofibrosis, experts from the John Theurer Cancer Center discuss the use of JAK inhibitors, specifically ruxolitinib, to manage patients in the frontline setting.

Key opinion leaders on myelofibrosis management consider the potential role of momelotinib within the current treatment paradigm.

Shared insight on the safety profile of pacritinib and how best to mitigate or manage adverse events when they occur in patients with myelofibrosis.

Experts continue their conversation on pacritinib in myelofibrosis by reviewing its potential impact on anemia and ACVR1.

Centering discussion on the JAK inhibitor pacritinib, expert panelists review data from recent clinical trials and consider how they inform real-world use of this agent.

Key opinion leaders provide a broad perspective on the current treatment armamentarium available to patients diagnosed with myelofibrosis.

A comprehensive discussion on the members of a healthcare team who might help to diagnose and manage a patient with myelofibrosis.

Expert panelists consider key molecular markers that guide the classification and management of myelofibrosis, along with other important subsets of disease.

After reviewing the first patient scenario of myelofibrosis, experts from the John Theurer Cancer Center reflect on best practices in diagnosing and risk stratifying patients.